home000A - Dr. Frances Kathleen Oldham Kelsey (born 1914)

Frances Kathleen Oldham Kelsey CM (née Oldham; July 24, 1914 – August 7, 2015) was a Canadian-American[1] pharmacologist and physician. As a reviewer for the U.S. Food and Drug Administration (FDA), she refused to authorize thalidomide for market because she had concerns about the lack of evidence regarding the drug's safety.[2] Her concerns proved to be justified when it was shown that thalidomide caused serious birth defects. Kelsey's career intersected with the passage of laws strengthening FDA oversight of pharmaceuticals. Kelsey was the second woman to receive the President's Award for Distinguished Federal Civilian Service, awarded to her by John F. Kennedy in 1962.

Birth and education[edit]

Born in Cobble Hill, British Columbia,[3] Kelsey attended St. Margaret's School from 1928 to 1931 in the provincial capital, graduating at age 15.[4] From 1930 to 1931, she attended Victoria College (now University of Victoria). She then enrolled at McGill University, where she received both a B.Sc. (1934) and an M.Sc. (1935) in pharmacology.[3] Encouraged by one of her professors, she "wrote to EMK Geiling, M.D., a noted researcher [who] was starting up a new pharmacology department at the University of Chicago, asking for a position doing graduate work".[4] Geiling, unaware of spelling conventions with respect to Francis and Frances, presumed that Frances was a man and offered her the position, which she accepted, starting work in 1936.[5][6]

During Kelsey's second year, Geiling was retained by the FDA to research unusual deaths related to elixir sulfanilamide, a sulfonamide medicine. Kelsey assisted on this research project, which showed that the 107 deaths were caused by the use of diethylene glycol as a solvent. At that time, there was no law available to prosecute those who sold poison as medicine, and Kelsey observed the need to work around incomplete regulation.[7] The next year, the United States Congress passed the Federal Food, Drug, and Cosmetic Act of 1938.[4] That same year she completed her studies and received a Ph.D. in pharmacology at the University of Chicago.[4] Working with Geiling led to her interest in teratogens, drugs that cause congenital malformations (birth defects).[8] She learned about the mechanism by which birth defects occur.[7]

Academic career[edit]

Kelsey in the 1960s

Upon completing her Ph.D., Oldham joined the University of Chicago faculty. In 1942, like many other pharmacologists, Oldham was looking for a synthetic cure for malaria. As a result of these studies, Oldham learned that some drugs are able to pass through the placental barrier.[9] During her work, she also met fellow faculty member [Dr. Fremont Ellis Kelsey (born 1912)], whom she married in 1943.[4]

While on the faculty at the University of Chicago, Kelsey was awarded her M.D. in 1950.[4] She supplemented her teaching with work as an editorial associate for the American Medical Association Journal for two years. Kelsey left the University of Chicago in 1954, decided to take a position teaching pharmacology at the University of South Dakota, and moved with her husband and two daughters to Vermillion, South Dakota, where she taught until 1957.[3]

She became a dual citizen of Canada and the United States in the 1950s in order to continue practicing medicine in the U.S., but retained strong ties to Canada where she continued to visit her siblings regularly until late in life.[2]

Work on thalidomide[edit]

Kelsey received the President's Award for Distinguished Federal Civilian Service from President John F. Kennedy, 1962

In 1960, Kelsey was hired by the FDA in Washington, D.C. At that time, she "was one of only seven full-time and four young part-time physicians reviewing drugs"[4] for the FDA. One of her first assignments at the FDA was to review an application by Richardson-Merrell for the drug thalidomide (under the tradename Kevadon) as a tranquilizer and painkiller with specific indications to prescribe the drug to pregnant women for morning sickness. Although it had been previously approved in Canada and more than 20 European and African countries,[10] she withheld approval for the drug and requested to see clinical trial information.[3] At the time, the FDA could only withhold approval for 60 days at a time, so she continually requested further information from the company every 60 days for over a year. Her initial reason for doing this was that the testimonials supplied by Richardson-Merrell contained no scientific methodology, and she recognized their authors as having published suspicious articles in the past.[11][7]

In December 1960, Leslie Florence published a letter in the British Medical Journal connecting thalidomide to neurological symptoms. Kelsey saw this letter and added Florence's observed symptoms to her ongoing data requests.[4][12] The unexpected neurological effects caused her to recall her earlier work on the mechanism of birth defects, so she also requested animal studies to demonstrate that the drug would not be harmful to the fetus.[7][12] In fact, Richardson-Merrell had reportedly discovered birth defects when the drug was tested on rats but did not report this finding; Kelsey was instead sent misleading partial data suggesting the product was safe for pregnant women. Despite the fact that thalidomide was already widely used in Europe and elsewhere, Kelsey remained suspicious and scrutinized this data with concern and skepticism, sometimes asking her husband to check her conclusions.[13] As 1960 turned to 1961, Kelsey's continual requests for more information incurred the ire of her contact at Richardson-Merrell, who insisted on speeding up the approval process and attempted to escalate the application, but Kelsey's superiors at the FDA stood by her.[7]

Kelsey's insistence that the drug should be fully tested prior to approval was vindicated in November 1961 when the births of deformed infants in Europe were linked to thalidomide ingestion by their mothers during pregnancy.[14][15] Researchers discovered that the thalidomide crossed the placental barrier and caused serious birth defects.[9] In March 1962, after distributing "experimental" tablets to tens of thousands of patients without approval (causing 17 malformed births), Richardson-Merrell at last withdrew their FDA application.[16] Kelsey was hailed on the front page of The Washington Post as a heroine[17] for averting a large-scale tragedy in the U.S.[18] Morton Mintz, author of The Washington Post article, said "[Kelsey] prevented ... the birth of hundreds or indeed thousands of armless and legless children."[17] Kelsey insisted that her assistants, Oyama Jiro and Lee Geismar, as well as her FDA superiors who backed her strong stance, deserved credit as well. The narrative of Kelsey's persistence was used to help pass rigorous drug approval regulation in 1962.[1]

After Mintz broke the story in July 1962, there was a substantial public outcry. The Kefauver Harris Amendment was passed unanimously by Congress in October 1962 to strengthen drug regulation.[14][15] Companies were required to demonstrate the efficacy of new drugs, report adverse reactions to the FDA, and request consent from patients participating in clinical studies.[19] The drug testing reforms required "stricter limits on the testing and distribution of new drugs"[9] to avoid similar problems. The amendments, for the first time, also recognized that "effectiveness [should be] required to be established prior to marketing."[14][15]

As a result of her blocking American approval of thalidomide, Kelsey was awarded the President's Award for Distinguished Federal Civilian Service by John F. Kennedy on August 7, 1962,[20] becoming the second woman so honoured.[21] After receiving the award, Kelsey continued her work at the FDA. There, she played a key role in shaping and enforcing the 1962 amendments.[18] She was named Director of the Investigational Drug Branch.[3]

Further FDA career[edit]

In 1966, Lyndon B. Johnson appointed James L. Goddard as Commissioner of Food and Drugs. Goddard resented the public attention Kelsey continued to receive and believed widespread rumors spread by pharmaceutical industry executives that Kelsey had delayed the thalidomide application through pure laziness. This was precisely the opposite of the truth: most applications were automatically approved by reviewers ignoring the 60 day deadline, while Kelsey had carefully sent out data requests for over a year. Regardless, Kelsey was demoted from Director of the Investigational Drug Branch to Chief of the Division of Oncology and Radiopharmaceutical Drug Products, where she was given little work.[22]

After Goddard's departure, Kelsey was again appointed Director of Scientific Investigations, and continued in this position for many decades. She was involved in the contentious regulation of diethylstilbestrol, which also caused birth defects, and dimethyl sulfoxide. In 1994, the Frances Kelsey Secondary School in Mill Bay, British Columbia, was named in her honour.[23] She attended the opening ceremony despite having suffered broken ribs and a vertebral compression fracture on the way to the ceremony. In 1995, when she was eighty-one, the FDA's Center for Drug Evaluation and Research created a special position for her, Deputy for Scientific and Medical Affairs in the Office of Compliance.[24]

Later life and death[edit]

Kelsey (age 87) at the FDA reception commemorating her induction into the National Women's Hall of Fame

Kelsey retired from the FDA in 2005, at age 90, after 45 years of service.[10] In 2010, the FDA presented Kelsey with the first Drug Safety Excellence Award and named the award after her,[25][26] announcing that it would be given to one FDA staff member annually.[27] In announcing the awards, Center Director Steven K. Galson said: "I am very pleased to have established the Dr. Frances O. Kelsey Drug Safety Excellence Award and to recognize the first recipients for their outstanding accomplishments in this important aspect of drug regulation."[28]

Kelsey turned 100 in July 2014,[29] and shortly thereafter, in the fall of 2014, she moved from Washington, D.C., to live with her daughter in London, Ontario.[30] In June 2015, when she was named to the Order of Canada, Mercédes Benegbi, a thalidomide victim and the head of the Thalidomide Victims Association of Canada, praised Kelsey for showing strength and courage by refusing to bend to pressure from drug company officials, and said "To us, she was always our heroine, even if what she did was in another country."[30]

Kelsey died in London, Ontario, on August 7, 2015, at the age of 101,[31] less than 24 hours after Ontario's Lieutenant-Governor, Elizabeth Dowdeswell, visited her home to present her with the insignia of Member of the Order of Canada.[32]

Legacy and awards

The "Drug Detective"

1962 • President's Award for Distinguished Federal Civilian Service [10]
1963 • Gold Key Award from University of Chicago, Medical and Biological Sciences Alumni Association[33]
1994 • Chosen as the namesake for Frances Kelsey Secondary School which opened in 1995.
2000 • Inducted into the National Women's Hall of Fame [21]
2001 • Named a Virtual Mentor for the American Medical Association[34]
2006 • Foremother Award from the National Center for Health Research [35]
2010 • Recipient of the first Dr. Frances O. Kelsey Award for Excellence and Courage in Protecting Public Health given out by the FDA[36]
2012 • Honorary doctor of science degree from Vancouver Island University [37]
2015 • Named to the Order of Canada [30]

Biographies

Essinger, James; Koutzenko, Sandra (2018). Frankie: how one woman prevented a pharmaceutical disaster. North Palm Beach, Florida: Blue Sparrow Books. ISBN 978-1635820461.
Vanderbes, Jennifer (2023). Wonder drug: the secret history of Thalidomide in America and its hidden victims. New York: Random House. ISBN 978-0525512264.
Warsh, Cheryl Krasnick (2024). Frances Oldham Kelsey, the FDA, and the battle against thalidomide. New York: Oxford University Press. ISBN 978-0197632543.

References

a b McFadden, Robert (August 7, 2015), "Frances Oldham Kelsey, F.D.A. Stickler Who Saved U.S. Babies From Thalidomide, Dies at 101", The New York Times.
a b Peritz, Ingrid (November 24, 2014), "Canadian doctor averted disaster by keeping thalidomide out of the U.S.", The Globe and Mail, retrieved August 7, 2015.
a b c d e "Frances Kelsey", Canada Heirloom Series, Heirloom Publishing Inc., 986, retrieved August 15, 2009.
a b c d e f g h Bren, Linda (March–April 2001), "Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on History", FDA Consumer, 35 (2): 24–29, PMID 11444245, archived from the original on October 20, 2006, retrieved August 15, 2009.
^ "When Kelsey read Geiling's letter offering her a research assistantship and scholarship in the PhD program at Chicago, she was delighted. But there was one slight problem — one that 'tweaked her conscience a bit.' The letter began 'Dear Mr. Oldham,' Oldham being her maiden name. Kelsey asked her professor at McGill if she should wire back and explain that Frances with an 'e' is female. 'Don't be ridiculous,' he said. 'Accept the job, sign your name, put 'Miss' in brackets afterwards, and go!'" Bren (2001).
^ Johnson, Steven (2021). Extra Life (1st ed.). Riverhead Books. p. 132. ISBN 978-0-525-53885-1.
a b c d e Scheindlin, S. (February 1, 2011). "The Courage of One's Convictions: THE DUE DILIGENCE OF FRANCES OLDHAM KELSEY AT THE FDA". Molecular Interventions. 11 (1): 3–9. doi:10.1124/mi.11.1.1. PMID 21441115.
^ Spiegel, Rachel, Research in the News: Thalidomide, archived from the original on August 22, 2007, retrieved August 15, 2009.
a b c Simpson, Joanne Cavanaugh (September 2001), "Pregnant Pause", Johns Hopkins Magazine, 53 (4), retrieved April 30, 2006.
a b c Rouhi, Maureen (June 20, 2005), "Top Pharmaceuticals: Thalidomide", Chemical & Engineering News, 83 (25), doi:10.1021/cen-v083n025.p122, retrieved April 30, 2006.
^ Kriplen, Nancy (2017). "The Heroine of the FDA". Discover Magazine. Retrieved July 21, 2024.
a b Phillips, Stephen (March 9, 2020). "How a courageous physician-scientist saved the U.S. from a birth-defects catastrophe". UChicago Medicine. Retrieved May 6, 2020.
^ Warsh, Cheryl Krasnick (2024). Frances Oldham Kelsey, the FDA, and the battle against thalidomide. New York: Oxford University Press. pp. 108, 109, 342n48. ISBN 978-0197632543.
a b c "The Story Of The Laws Behind The Labels", FDA Consumer, June 1981, archived from the original on August 16, 2009, retrieved August 15, 2009
a b c "The Story Of The Laws Behind The Labels", FDA Consumer, June 1981, retrieved March 15, 2022.
^ Magazine, Smithsonian; McNeill, Leila. "The Woman Who Stood Between America and a Generation of 'Thalidomide Babies'". Smithsonian Magazine. Retrieved July 21, 2024.
a b Mintz, Morton (July 15, 1962), "'Heroine' of FDA Keeps Bad Drug Off of Market", The Washington Post, p. Front Page. See also Mintz's comments from 2005 on Kelsey.
a b Dr. Frances Kathleen Oldham Kelsey, National Library of Medicine, retrieved April 30, 2006.
^ Frances Oldham Kelsey, Chemical Heritage Foundation, archived from the original on July 12, 2016, retrieved March 23, 2014
^ Kennedy, John F. (1962), Remarks Upon Presenting the President's Awards for Distinguished Federal Civilian Service, retrieved May 1, 2006.
a b Women of the Hall – Frances Kathleen Oldham Kelsey, Ph.D., M.D., National Women's Hall of Fame, 2000, archived from the original on October 3, 2002, retrieved May 1, 2006.
^ Warsh, Cheryl Krasnick (2024). Frances Oldham Kelsey, the FDA, and the battle against thalidomide. New York: Oxford University Press. pp. 211–212. ISBN 978-0197632543.
^ FKSS History, Frances Kelsey Secondary School, archived from the original on October 19, 2012, retrieved December 26, 2014.
^ Warsh, Cheryl Krasnick (2024). Frances Oldham Kelsey, the FDA, and the battle against thalidomide. New York: Oxford University Press. p. 304. ISBN 978-0197632543.
^ Harris, Gardiner (September 13, 2010), "The Public's Quiet Savior From Harmful Medicines", The New York Times, retrieved January 4, 2011.
^ Lyndsey Layton (September 13, 2010), "Physician to be honored for historic decision on thalidomide", The Washington Post.
^ Margaret A. Hamburg, M.D., Commissioner of Food and Drugs – Remarks at the Award Ceremony for Dr. Frances Kelsey.
^ Barber, Jackie (November 10, 2005), "Center ceremony honors 107 individuals, 47 groups: Spring event inaugurates Frances Kelsey Drug Safety Award", News Along the Pike, archived from the original on June 15, 2007, retrieved August 15, 2009.
^ McElroy, Justin (July 24, 2014), Canadian scientist Frances Kelsey, who spurred FDA reforms, turns 100, Global News, retrieved July 24, 2014.
a b c Ingrid Peritz (July 1, 2015), "Doctor who opposed thalidomide in U.S. named to Order of Canada", The Globe and Mail, retrieved July 1, 2015.
^ Bernstein, Adam; Sullivan, Patricia (August 7, 2015), "Frances Oldham Kelsey, FDA scientist who kept thalidomide off U.S. market, dies at 101", The Washington Post, retrieved August 7, 2015.
^ Ingrid Peritz (August 7, 2015), "Canadian doctor who kept thalidomide out of U.S. dies", The Globe and Mail, retrieved August 7, 2015.
^ Gold Key Award Recipients, The University of Chicago The Medical & Biological Sciences Alumni Association, retrieved August 14, 2006.
^ Geraghty, Karen (July 2001), "Profile of a Role Model – Frances Oldham Kelsey, MD, PhD", Virtual Mentor – American Medical Association Journal of Ethics, 7 (7), archived from the original on September 29, 2007, retrieved August 15, 2009.
^ "Foremother and Health Policy Hero Awards Luncheon". May 7, 2018.
^ "FDA honors one of its own". CNN blog. September 16, 2010. Archived from the original on September 30, 2017. Retrieved August 9, 2015.
^ "Honorary doctor of science degree from Vancouver Island University", Nanaimo News Bulletin, Black Press, Inc., June 6, 2012, archived from the original on June 6, 2014, retrieved June 27, 2012.